New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
14:01 EDTOPKOPKO Health reports positive interim six-month Lagova Phase 2 data
OPKO Health announced 6 month results of a Phase 2 dose-finding study evaluating the safety and efficacy of its novel long-acting human growth hormone product to treat pediatric growth hormone deficiency disorder. All three Lagova once-weekly doses demonstrate strong catch-up growth during the six months treatment. The annualized growth rates are above 12 cm in all three doses. The results are supported by excellent dose dependent pharmacokinetics and pharmacodynamics profiles. Lagova shows a promising safety profile with no serious adverse events reported. Glucose and lipid metabolism markers are within the normal ranges. No lipoatrophy was observed in any patients dosed, and no clinically significant local tolerability issues were identified. “Based on these encouraging safety and efficacy results, OPKO plans to move aggressively into a single confirmatory pivotal Phase 3 study for pediatric GHD patients. We hope to make Lagova available to pediatric GHD patients as soon as possible,” said CEO, Phillip Frost, M.D. “Lagova is one of a family of important products being developed at OPKO Biologics designed to improve compliance and offer ease of administration to patients.”
News For OPK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
10:40 EDTOPKOPKO Health deal with Pfizer removes financing overhang, says Ladenburg
Ladenburg views the agreement OPKO Health (OPK) signed with Pfizer (PFE) as a significant positive catalyst since the company is partnering with an established leader in short-acting hGH and because the large upfront payment removes near-term financing needs as an overhang on the stock. The firm reiterates its Buy rating and $14.50 price target on OPKO, but said it will re-examine its projections after the deal closes.
10:19 EDTOPKOPKO Health soars after entering hGP-CTP agreement with Pfizer
Subscribe for More Information
09:38 EDTOPKActive equity options trading
Subscribe for More Information
09:27 EDTOPKOn The Fly: Pre-market Movers
HIGHER: Opko Health (OPK), up 13.1% after Pfizer (PFE) and OPKO Health enter into global agreement for hGH-CTP... Cirrus Logic (CRUS), up 7.5% after being upgraded to Overweight from Underweight at Barclays... PetSmart (PETM), up 4.7% after being acquired by BC Partners led consortium for $83 per share... Sohu.com (SOHU), up 3% after being upgraded to Overweight from Neutral at JPMorgan... Oracle (ORCL), up 2.2% after receiving FedRAMP provisional authority to operate. LOWER: Unwired Planet (UPIP), down 25.7% after commenting on Google (GOOG) Markman ruling... EXCO Resources (XCO), down 13% after suspending its dividend.
08:02 EDTOPKPfizer, OPKO Health enter into global agreement for hGH-CTP
Subscribe for More Information
December 10, 2014
06:00 EDTOPKStocks with implied volatility above IV index mean; DG OPK
Stocks with implied volatility above IV index mean; OPKO Health (OPK) 36, Dollar General (DG) 37 according to iVolatility.
December 9, 2014
06:07 EDTOPKStocks with implied volatility above IV index mean; DG OPK
Stocks with implied volatility above IV index mean; OPKO Health (OPK) 41, Dollar General (DG) 37 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use